AL Amyloidosis
Efstathios Kastritis, MD
National and Kapodistrian University of Athens
Updated results for the treatment of AL amyloidosis were also presented in both meetings.
In the ANDROMEDA trial, the combination of subcutaneous daratumumab with VCD plus daratumumab maintenance was compared to VCD alone in newly diagnosed patients with AL amyloidosis. In the update of the study that was reported in both ASCO (Abstract 8003) and EHA (abstract S189) by Prof E. Kastritis, (median follow up 20.3 months) the complete hematologic response rates remained significantly higher for Dara-VCd (59% vs 19%), across all major subgroups and at 12-month landmark cardiac responses were 57% vs 28% (improved from 42% vs 22% at 6 months) and renal responses were 57% vs 27%. There were no new safety findings with additional follow-up, in the D-VCd group during treatment with daratumumab monotherapy after cycle 6.
Why Become a Member
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
